Barin Feroz

Innsbruck, 6020, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Early Normalization of Squamous Cell Carcinoma Antigen During Combined Chemoradiation Predicts Pathological Response and Survival in Squamous Cervical Cancer: A Retrospective Cohort Study.

Early Normalization of Squamous Cell Carcinoma Antigen During Combined Chemoradiation Predicts Pathological Response and Survival in Squamous Cervical Cancer: A Retrospective Cohort Study.

Journal: Cancers
Published: June 16, 2026

Intensity-modulated radiotherapy/Volumetric modulated Arc therapy including four Brachytherapy fractions versus 3D conformal radiotherapy containing five Brachytherapy fractions in the treatment of cervical cancer.

Intensity-modulated radiotherapy/Volumetric modulated Arc therapy including four Brachytherapy fractions versus 3D conformal radiotherapy containing five Brachytherapy fractions in the treatment of cervical cancer.

Journal: Radiation oncology (London, England)
Published: December 10, 2025

The Role of Plasmacytoid Dendritic Cells in the Immune Contexture of TP53-Mutated High-Grade Serous Ovarian Cancer.

The Role of Plasmacytoid Dendritic Cells in the Immune Contexture of TP53-Mutated High-Grade Serous Ovarian Cancer.

Journal: Cancers
Published: October 26, 2025

Comparison of Efficacy and Safety of Cryotherapy in Chemotherapy-Induced Peripheral Neuropathy Between Upper and Lower Extremities: Results from the Randomized CROPSI Study.

Comparison of Efficacy and Safety of Cryotherapy in Chemotherapy-Induced Peripheral Neuropathy Between Upper and Lower Extremities: Results from the Randomized CROPSI Study.

Journal: Cancers
Published: April 28, 2025

Biopsy-proven residual cervical cancer at the end of combined chemoradiation predicts poor outcome-Retrospective single-center cohort study.

Biopsy-proven residual cervical cancer at the end of combined chemoradiation predicts poor outcome-Retrospective single-center cohort study.

Journal: Acta obstetricia et gynecologica Scandinavica
Published: April 28, 2025

Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer.

Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)
Published: December 02, 2024

Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcome.

Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcome.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: July 05, 2024

Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysis.

Pegylated liposomal doxorubicin combined with trabectedin as a treatment option in uterine sarcomas: a single-institution retrospective analysis.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: April 30, 2024
Showing 1-8 of 8

Last Updated: 09/26/2026